The antitumor effects of aspirin combined with anti-PD-L1 blockade have been evaluated in mouse models, and an ongoing clinical trial (NCT 02659384) in Switzerland is assessing the effects of aspirin plus anti-PD-L1 antibodies (atezolizumab, bevacizumab) in ovarian cancer. This evidence concerns the gene CD274 and ovarian carcinoma.